Gene Discovery News: Breaking Gene Discovery News, Comments and Articles. - Page: 5

17:23 EST 18th December 2014 | BioPortfolio

Gene Discovery News - Page: 5RSS

Read the latest Gene Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Gene Discovery.

Search or Follow Our Gene Discovery - Page: 5 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Gene Discovery - Page: 5 News.

Showing "gene discovery" News Articles 101 to 125 of 7,700+

Tuesday 16th December 2014

Prima BioMed Completes Immutep Acquisition

SYDNEY, AUSTRALIA -- (Marketwired) -- 12/17/14 -- Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima" or the "Company") announces that the acquisition of Immutep SA ("Immutep"), the French privately owned biopharmaceutical company in the rapidly growing field of Immuno-Oncology, has been completed. Prima also announces that Professor Frédéric Triebel has joined the Company as its new Chief Sci...

Quincy Bioscience Kicks Off the 2015 Better Memory Tour

MADISON, WI--(Marketwired - December 17, 2014) - Quincy Bioscience announces the start of the 2015 Better Memory Tour. The Prevagen Express will travel to various health food centers and health expos across the country to educate the public on the importance of taking proactive steps toward better brain health. Free memory surveys that assess everyday working memory will be offered to all attende...

Anti-diabetic drug springs new hope for tuberculosis patients

(Biomedical Sciences Institutes (BMSI)) A more effective treatment for tuberculosis (TB) could soon be available as scientists have discovered that metformin, a drug for treating diabetes, can also be used to boost the efficacy of TB medication witho...

'Master regulator' gene -- long tied to autism disorders -- stimulates other genes in early brain development

(NYU Langone Medical Center / New York University School of Medicine) Chemical modifications to DNA's packaging -- known as epigenetic changes -- can activate or repress genes involved in autism spectrum disorders and early brain development, accordi...

Life Sciences Discovery Fund announces proof of concept awards, inaugural matching grants

(Life Sciences Discovery Fund) The Life Sciences Discovery Fund announced $1.2 million in Proof of Concept grants to Washington-based organizations to foster the advancement of promising health-related technologies to commercial products. Also announ...

Combining images, genetic data proves gene loss behind aggressive ovarian cancers

Loss of a gene called PTEN triggers some cases of an aggressive form of ovarian cancer, called high-grade serous ovarian cancer, researchers have demonstrated. In a revolutionary approach, the researchers made the discovery by combining images from c...

Patently Biotech’s Top Articles of 2014

It’s been a whirlwind year for IP. From international trade negotiations, to revised PTO guidelines and dropping patent case stats, intellectual property is on the brain and in the news. Here are Patently Biotech’s top blog posts of 2014: TPP and...

‘Genome Editing’ Could Correct Genetic Mutations for Future Generations

(Medical Xpress) – Scientists at Indiana University and colleagues at Stanford and the University of Texas have demonstrated a technique for “editing” the genome in sperm-producing adult stem cells, a result with powerful potential ...

Combining images and genetic data proves gene loss behind aggressive ovarian cancers

Cancer Research UK scientists have shown that loss of a gene called PTEN triggers some cases of an aggressive form of ovarian cancer, called high-grade serous ovarian cancer, according to a study published in Genome Biology today.

Alabama police find heroin in toddler's diaper, arrest father

(Reuters) - Police in Alabama arrested a man after finding 14 grams of heroin hidden in his 2-year-old daughter's diaper, a discovery aided by a tip from the girl's 5-year-old sister, authorities said on Tuesday. Narcotics detectives in the...

Boston Strategics Enters into an Innovative Risk-Sharing Agreement with the MD Anderson Cancer Center to Conduct a Phase 1/2a Clinical Trial of E6201 in Patients with Advanced Hematologic Malignancies Including Acute Myeloid Leukemia

Boston Strategics Corporation (BSC), an integrated clinical-stage drug research and development (R&D) company, Boston, MA, today announced that it has entered into a risk-sharing agreement with

Exact raises $103M in follow-on

Exact Sciences Corp. (NASDAQ:EXAS) raised $103 million through the sale of 4 million shares at $25.75 in a follow-on underwritten by Jefferies and Baird. FDA approved Exact's Cologuard in August. The non-invasive DNA screening test for colorectal can...

The p53-induced lincRNA-p21 derails somatic cell reprogramming by sustaining H3K9me3 and CpG methylation at pluripotency gene promoters

Fourth round brings NOK90mm to BerGenBio

Cancer drug discovery firm BerGenBio AS raised NOK90mm ($15mm) through its Series D round to new and existing investors. Proceeds will go towards ongoing Phase Ib trials of BGB324, an Axl kinase inhibitor for acute myeloid leukemia; the compound just...

Alexion, X-Chem ally in severe ultra-rare conditions

X-Chem Inc. (a wholly owned subsidiary of Pharmaceutical Product Development) agreed to use its drug discovery platform and diverse 100 billion-molecule library to identify candidates against ultra-rare disease targets provided by Alexion Pharmaceut...

Selvita Has Raised PLN 27.3 MM on its Way to the Main Market of the Warsaw Stock Exchange

Krakow, Poland, December 16 2014 / B3C newswire / - Selvita, Poland-based integrated drug discovery partner for the pharmaceutical and biotechnology industry, has successfully completed its Initial Public Offering. Gross proceeds from the sale of 2,651,891 new shares amount to PLN 27.3 MM (US$ 8.1 MM), sold at the maximum announced price. Selvita plans to enter the main market of the Warsaw Stock...

7q11.23 dosage-dependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease-relevant lineages

Giuseppe Testa and colleagues report the generation and transcriptional characterization of patient-derived induced pluripotent stem cells (iPSCs) with copy number variants at 7q11.23, which cause syndromes including neurocognitive phenotypes. They f...

Is Hair Dye a Health Hazard?

In the mid-1800s, English chemist William Henry Perkin serendipitously synthesized the first non-natural dye: starting with coal tar, he was hoping to produce the malaria drug quinine but instead created mauve. His discovery revolutionized the textil...

Gift to Mount Sinai Health System Establishes Ronald M. Loeb Center for Alzheimer’s Disease

$15 Million Gift By Daniel and Margaret Loeb in Memory of Ronald M. Loeb; Center Dedicated to Alzheimer’s Disease Research New York, NY (PRWEB) December 16, 2014 The Mount Sinai Health System today announced that Daniel S. Loeb, CEO and Founder of Third Point LLC, and his wife, Margaret Munzer Loeb, have made a $15 million gift to establish the Ronald M. Loeb Center for Alzheimer’s Disease in...

New method identifies genome-wide off-target cleavage sites of CRISPR-Cas nucleases

Massachusetts General Hospital (MGH) investigators have developed a method of detecting, across the entire genome of human cells, unwanted DNA breaks induced by use of the popular gene-editing tools called CRISPR-Cas RNA-guided nucleases (RGNs). Memb...

Spark Therapeutics appoints Rogerio Vivaldi as its first chief commercial officer

Late-stage gene therapy company, Spark Therapeutics, has appointed Rogerio Vivaldi as its first chief commercial officer.

Developing a xylanase XYNZG from Plectosphaerella Cucumerina for baking by heterologously expressed in Kluyveromyces lactis

Background: Xylanase can replace chemical additives to improve the volume and sensory properties of bread in the baking. Suitable baking xylanase with improved yield will promote the application of xylanase in baking industry. The xylanase XYNZG from...

Antibodies Discovery Could Lead to Universal Dengue Vaccine

A major new class of antibodies that can make the four different types of dengue virus (DENV) non-infectious has been discovered by a group of international researchers, including from the University of Melbourne. The discovery could lead to the development of better vaccines and laboratory tests  that eventually could lead to reductions in the incidence of dengue. Publ

An Interview with Proteins Industry Leader Marco Thomann, Group Leader, Development Analytics Characterization, Roche.

Oxford Global Conferences are proud to present the 8th Annual Proteins & Antibodies Congress, taking place at the Novotel London West on the 20th and 21st April 2015. Our 8th Annual Proteins & Antibodies Congress is Europe’s leading congress on proteins and antibodies, bringing together over 350 senior-level decision makers working at the forefront of research into <!--LGfEGNT2L...

An Interview with Peptides Industry Leader Paul Feldman, Senior Vice President, GlaxoSmithKline.

Oxford Global Conferences are proud to present the 2nd Annual Peptides Congress, taking place at the Novotel London West on the 20th and 21st April 2015. The conference provides an exclusive opportunity for over 350 experts working in different areas of the peptides industry to exchange their experiences, engage in scientific discussions and network with senior-level attendees about the most pre...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks